- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05743933
Cohort Study of Adrenogenic Autonomic Cortisol Secretion
February 16, 2023 updated by: Qifu Li, Chongqing Medical University
To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.
Study Overview
Status
Not yet recruiting
Detailed Description
With the development of imaging detection technology and its wide application in clinic, the detection rate of adrenal incidentaloma (AI) has been greatly improved.
In our previous study, 18.9% of AI were accompanied by autonomic cortisol secretion (ACS) in Chinese.
The vast majority of ACS is mild (MACS).
Due to the lack of typical Cushing manifestations and the low rate of progression to overt Cushing, MACS has received insufficient attention in the past.
However, recent studies have found that MACS have a higher incidence of diabetes, hypertension, cardiovascular events, metabolic bone disease and mortality risk than those with non-functional adenomas.
With appropriate treatment, the complications of MACS patients can be effectively improved.
However, personalized treatment of MACS is a clinical difficulty.
It is hard to determine whether the cortisol secretion of patients is caused by AI or whether patients will benifit from operation.
There are some retrospective studies have provided some evidence, while prospective studies are lacking.
The purpose of this study is to prospectively include patients with autonomic cortisol secretion, evaluate function and diagnosis, develop personalized treatment strategy, and follow up the prognosis.
The research results will provide new evidence for standardized diagnosis and treatment of adrenogenic autonomic cortisol secretion in the future.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qifu Li, PhD
- Phone Number: +86-023-89011552
- Email: liqifu@yeah.net
Study Contact Backup
- Name: Shumin Yang, PhD
- Phone Number: +86-023-89011552
- Email: 443068494@qq.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
People with adrenal incidentaloma and serum cortisol > 50nmol/L after 1mg dexamethasone inhibition test, without other situation mentioned in exclusion criteria.
Description
Inclusion Criteria:
- CT examination revealed adrenal nodules (maximum diameter ≥10mm);
- Serum cortisol > 50nmol/L after 1mg dexamethasone inhibition test (1mg-DST).
Exclusion Criteria:
- Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma/paraganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function.
- Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy.
- Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis.
- Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Study group
Accidental adrenal tumor with 1mg-DST cortisol >50nmol/L
|
Control group
Accidental adrenal tumor with 1mg-DST cortisol ≤50nmol/L
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SUVmax value of PET-CT
Time Frame: 10 years
|
To explore the value of 68[Ga]-Pentixafor PET-CT in the diagnosis of MACS
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Etiology and pathogenesis of adrenogenic autonomic cortisol secretion
Time Frame: 10 years
|
To study the etiology and pathogenesis of adrenogenic autonomic cortisol secretion
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Qifu Li, PhD, First Affiliated Hospital of Chongqing Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Jing Y, Hu J, Luo R, Mao Y, Luo Z, Zhang M, Yang J, Song Y, Feng Z, Wang Z, Cheng Q, Ma L, Yang Y, Zhong L, Du Z, Wang Y, Luo T, He W, Sun Y, Lv F, Li Q, Yang S. Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. Ann Intern Med. 2022 Oct;175(10):1383-1391. doi: 10.7326/M22-1619. Epub 2022 Sep 13.
- Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, Marina LV, Deutschbein T, Balomenaki M, O'Reilly MW, Gilligan LC, Jenkinson C, Bednarczuk T, Zhang CD, Dusek T, Diamantopoulos A, Asia M, Kondracka A, Li D, Masjkur JR, Quinkler M, Ueland GA, Dennedy MC, Beuschlein F, Tabarin A, Fassnacht M, Ivovic M, Terzolo M, Kastelan D, Young WF Jr, Manolopoulos KN, Ambroziak U, Vassiliadi DA, Taylor AE, Sitch AJ, Nirantharakumar K, Arlt W; ENSAT EURINE-ACT Investigators*; ENSAT EURINE-ACT Investigators. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med. 2022 Mar;175(3):325-334. doi: 10.7326/M21-1737. Epub 2022 Jan 4.
- Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, Nekic AB, Debono M, Lardo P, Ceccato F, Petramala L, Prete A, Chiodini I, Ivovic M, Pazaitou-Panayiotou K, Alexandraki KI, Hanzu FA, Loli P, Yener S, Langton K, Spyroglou A, Kocjan T, Zacharieva S, Valdes N, Ambroziak U, Suzuki M, Detomas M, Puglisi S, Tucci L, Delivanis DA, Margaritopoulos D, Dusek T, Maggio R, Scaroni C, Concistre A, Ronchi CL, Altieri B, Mosconi C, Diamantopoulos A, Iniguez-Ariza NM, Vicennati V, Pia A, Kroiss M, Kaltsas G, Chrisoulidou A, Marina LV, Morelli V, Arlt W, Letizia C, Boscaro M, Stigliano A, Kastelan D, Tsagarakis S, Athimulam S, Pagotto U, Maeder U, Falhammar H, Newell-Price J, Terzolo M, Fassnacht M. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol. 2022 Jul;10(7):499-508. doi: 10.1016/S2213-8587(22)00100-0. Epub 2022 May 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 17, 2023
Primary Completion (Anticipated)
February 15, 2033
Study Completion (Anticipated)
February 15, 2033
Study Registration Dates
First Submitted
February 16, 2023
First Submitted That Met QC Criteria
February 16, 2023
First Posted (Actual)
February 24, 2023
Study Record Updates
Last Update Posted (Actual)
February 24, 2023
Last Update Submitted That Met QC Criteria
February 16, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-China 2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment
-
Psychiatric Centre RigshospitaletAstraZenecaTerminatedMedical Treatment | Antipsychotic Treatment | Quality AssuranceDenmark
-
Vilniaus Implantologijos Centro (VIC) KlinikaInstitut Straumann AGActive, not recruitingSingle Implant; Immediate Implant Treatment; Early Implant TreatmentLithuania
-
Entheon Biomedical Corp.CompletedTreatment-resistant DepressionUnited States
-
Zagazig UniversityNot yet recruiting
-
Ajman UniversityCompletedTreatmentUnited Arab Emirates
-
Nanjing University School of MedicineCompleted
-
Eunice Kennedy Shriver National Institute of Child...Withdrawn
-
The University of Texas Health Science Center at...Patient-Centered Outcomes Research InstituteCompletedStandard Treatment Versus Engagement Focused TreatmentUnited States
-
Central Institute of Mental Health, MannheimNot yet recruitingSchizophrenia | Treatment Resistant SchizophreniaGermany
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia